COMMUNIQUÉS West-GlobeNewswire

ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease
17/10/2017
Narrated presentation of results available on ProMIS website TORONTO and CAMBRIDGE, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development [...]
Terveystalo Plc's ten largest shareholders after the completion of the Initial Public Offering
17/10/2017
TERVEYSTALO PLC STOCK EXCHANGE RELEASE October 17, 2017 at 2:30 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL [...]
ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING
17/10/2017
pdf version of press release This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for [...]
Inivata Highlights New Clinical Data on InVision(TM) ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017
17/10/2017
Inivata Highlights New Clinical Data on InVision(TM) ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 First data published using amplicon-based technology to detect ALK and ROS1 fusions Highly sensitive [...]
Arix Bioscience PLC: Appoints Giles Kerr to Board of Directors
17/10/2017
Arix Bioscience appoints Giles Kerr to Board of Directors LONDON, 17 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical [...]
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions
17/10/2017
YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18 th World Conference on Lung Cancer (WCLC) featured groundbreaking [...]
RÉALISATION DE L'ÉMISSION PAR GENFIT D'OBLIGATIONS À OPTION DE CONVERSION ET/OU D'ÉCHANGE EN ACTIONS NOUVELLES ET/OU EXISTANTES (« OCEANE ») A ÉCHÉANCE 2022 POUR UN MONTANT DE 180 MILLIONS D'EUROS
17/10/2017
REALISATION DE L'EMISSION PAR GENFIT D'OBLIGATIONS A OPTION DE CONVERSION ET/OU D'ECHANGE EN ACTIONS NOUVELLES ET/OU EXISTANTES (« OCEANE ») A ECHEANCE 2022 POUR UN MONTANT DE 180 MILLIONS D'EUROS Lille (France), [...]
GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANEs") DUE 2022
17/10/2017
GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANEs") DUE 2022 Lille (France), Cambridge (Massachusetts, United States), October 17 th , 2017 [...]
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China
17/10/2017
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China Lugano, Switzerland, October 17, 2017 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces [...]
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions
17/10/2017
YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18 th World Conference on Lung Cancer (WCLC) featured groundbreaking [...]
Conférence de presse du dimanche de la Conférence mondiale sur le cancer du poumon : présentation de nouveaux prix et lignes directrices mondiales
17/10/2017
YOKOHAMA, Japon, le 15 octobre 2017 (GLOBE NEWSWIRE) - Le premier point-presse à l'occasion de la 18e Conférence mondiale sur le cancer du poumon (World Conference on Lung Cancer - WCLC) de l'IASLC (International [...]
Ossur Hf : Transactions in relation to share buyback program
16/10/2017
Announcement from Össur hf. No. 73/2017 Reykjavík, 16 October 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Invitation to Idorsia's nine-month results 2017 webcast and conference call
16/10/2017
Idorsia will publish its financial results for the first nine months of 2017 on Tuesday 24 October 2017 at 07:00 hrs CEST An investor conference call and webcast will be held to discuss the results on the same day at 15 [...]
LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin
16/10/2017
· Company co-founder Professor Adi Barzel, Ph.D., to present new proof-of-concept efficacy data CAMBRIDGE, Massachusetts, Oct. 16, 2017 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc., a gene-therapy company with a [...]
Medtronic Care Management Services and American Well Announce Strategic Partnership to Integrate Telehealth Capabilities
16/10/2017
Partnership Focused on Enabling Care for Chronic, Co-Morbid Patients DUBLIN and BOSTON - October 16, 2017 - Medtronic plc (NYSE:MDT) today announced its Medtronic Care Management Services (MCMS) business and American [...]
Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide
16/10/2017
PR171016_Semaglutide-briefing_books_UK This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]
Genedrive PLC: genedrive signs distribution agreement with Sysmex Europe GmbH("Sysmex Europe")
16/10/2017
For release: 16 October 2017 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the [...]
Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
16/10/2017
Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis - Late-breaking oral abstract presented at the World Congress of [...]
Sanofi et Regeneron annoncent les résultats positifs d'une étude de phase 2 du dupilumab dans le traitement de l'oesophagite à éosinophiles modérée à sévère de l'adulte
16/10/2017
Sanofi et Regeneron annoncent les résultats positifs d'une étude de phase 2 du dupilumab dans le traitement de l'oesophagite à éosinophiles modérée à sévère de l'adulte - Présentation spéciale de l'abstract de l'étude [...]

Pages